These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27393200)

  • 1. [Not Available].
    Muret P; Solas C;
    Therapie; 2011; 66(3):207-12. PubMed ID: 27393200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evidence-based therapeutic drug monitoring for saquinavir].
    Muret P; Solas C;
    Therapie; 2011; 66(3):207-12. PubMed ID: 21819804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Solas C; Muret P;
    Therapie; 2011; 66(3):213-9. PubMed ID: 27393201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Muret P; Piedoux S; Solas C; Quaranta S;
    Therapie; 2011; 66(3):187-95. PubMed ID: 27393198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence-based therapeutic drug monitoring of atazanavir].
    Solas C; Muret P;
    Therapie; 2011; 66(3):213-9. PubMed ID: 21819805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):239-46. PubMed ID: 27393204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):231-8. PubMed ID: 27393203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Solas C; Gagnieu MC;
    Therapie; 2011; 66(3):197-205. PubMed ID: 27393199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evidence-based therapeutic drug monitoring for nevirapine].
    Muret P; Piedoux S; Solas C; Quaranta S;
    Therapie; 2011; 66(3):187-95. PubMed ID: 21819802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Solas C; Paré M; Quaranta S; Stanke-Labesque F;
    Therapie; 2011; 66(3):221-30. PubMed ID: 27393202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.
    Smith GH; Boulassel MR; Klien M; Gilmore N; MacLeod J; LeBlanc R; René P; Routy JP; Lalonde RG
    HIV Clin Trials; 2005; 6(2):63-72. PubMed ID: 15983890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Charles M; Le Guellec C; Richard D; Libert F;
    Therapie; 2011; 66(2):103-8. PubMed ID: 27393644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Goirand F; Royer B; Hulin A; Saint-Marcoux F;
    Therapie; 2011; 66(1):57-61. PubMed ID: 27393466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Marcelin AG; Dalban C; Peytavin G; Lamotte C; Agher R; Delaugerre C; Wirden M; Conan F; Dantin S; Katlama C; Costagliola D; Calvez V
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4687-92. PubMed ID: 15561845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evidence-based therapeutic drug monitoring for indinavir].
    Barrail-Tran A; Taburet AM; Poirier JM;
    Therapie; 2011; 66(3):239-46. PubMed ID: 21819808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
    Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
    Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
    Marin-Niebla A; Lopez-Cortes LF; Ruiz-Valderas R; Viciana P; Mata R; Gutierrez A; Pascual R; Rodriguez M
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2035-42. PubMed ID: 17371813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.
    Grub S; Delora P; Lüdin E; Duff F; Fletcher CV; Brundage RC; Kline MW; Calles NR; Schwarzwald H; Jorga K
    Clin Pharmacol Ther; 2002 Mar; 71(3):122-30. PubMed ID: 11907486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.